相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update
Andrea Eisen et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Biological Effects of Cyclin-Dependent Kinase Inhibitors Ribociclib, Palbociclib and Abemaciclib on Breast Cancer Bone Microenvironment
Michele Iuliani et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
N. Harbeck et al.
ANNALS OF ONCOLOGY (2021)
Androgen receptor signaling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration-sensitive prostate cancer
Nicholas Mitsiades et al.
ENDOCRINE-RELATED CANCER (2021)
Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment A Phase 3 Randomized Clinical Trial
Thomas W. P. Friedl et al.
JAMA ONCOLOGY (2021)
Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer
Komal Waqas et al.
JOURNAL OF BONE ONCOLOGY (2021)
Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307
Julie R. Gralow et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
Management manual for cancer treatment-induced bone loss (CTIBL): position statement of the JSBMR
Seiji Fukumoto et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2020)
Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future
Laura M Spring et al.
LANCET (2020)
Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial
Robert Coleman et al.
LANCET ONCOLOGY (2020)
Bone health in cancer: ESMO Clinical Practice Guidelines
R. Coleman et al.
ANNALS OF ONCOLOGY (2020)
Does the Addition of Abiraterone to Castration Affect the Reduction in Bone Mineral Density?
Shiori Nakajima et al.
IN VIVO (2020)
Osteoporotic Fractures of the Spine, Hip, and Other Locations after Adjuvant Endocrine Therapy with Aromatase Inhibitors in Breast Cancer Patients: a Meta-analysis
Young-Kyun Lee et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2020)
Effects of denosumab on bone mineral density in Japanese women with osteoporosis treated with aromatase inhibitors for breast cancer
Katsuhiko Nakatsukasa et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2019)
Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial
Lorenzo Livi et al.
EUROPEAN JOURNAL OF CANCER (2019)
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
Karim Fizazi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Performance of FRAX in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study
William D. Leslie et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2019)
Incidence of fractures in young women with breast cancer - a retrospective cohort study
Ulla Stumpf et al.
JOURNAL OF BONE ONCOLOGY (2019)
Patients with prostate cancer and androgen deprivation therapy have increased risk of fracturesa study from the fractures and fall injuries in the elderly cohort (FRAILCO)
M. Wallander et al.
OSTEOPOROSIS INTERNATIONAL (2019)
Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis
Hadar Goldvaser et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
The effect of exercise on bone mineral density in adult cancer survivors: a systematic review and meta-analysis
J. Dalla Via et al.
OSTEOPOROSIS INTERNATIONAL (2018)
Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis
Hadar Goldvaser et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Adjuvant zoledronic acid reduces fractures in breast cancer patients; an AZURE (BIG 01/04) study
C. Wilson et al.
EUROPEAN JOURNAL OF CANCER (2018)
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
Maha Hussain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
Matthew R. Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015
A. Khan et al.
OSTEOPOROSIS INTERNATIONAL (2016)
Enzalutamide Reduces the Bone Mass in the Axial But Not the Appendicular Skeleton in Male Mice
Jianyao Wu et al.
ENDOCRINOLOGY (2016)
A concise review of testosterone and bone health
Nur-Vaizura Mohamad et al.
CLINICAL INTERVENTIONS IN AGING (2016)
5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial
Nina D. Wagner-Johnston et al.
CANCER (2015)
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial
Michael Gnant et al.
LANCET (2015)
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials
R. Coleman et al.
LANCET (2015)
Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial
S. L. Greenspan et al.
OSTEOPOROSIS INTERNATIONAL (2015)
Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment
Michele Iuliani et al.
ONCOTARGET (2015)
Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy
M. Kalder et al.
OSTEOPOROSIS INTERNATIONAL (2015)
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
Olivia Pagani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bone complications among prostate cancer survivors: long-term follow-up from the prostate cancer outcomes study
A. K. Morgans et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2014)
Worldwide uptake of FRAX
J. A. Kanis et al.
ARCHIVES OF OSTEOPOROSIS (2014)
The Efficacy of Bisphosphonates in Preventing Aromatase Inhibitor Induced Bone Loss for Postmenopausal Women with Early Breast Cancer: A Systematic Review and Meta-Analysis
Pooleriveetil Padikkal Anagha et al.
JOURNAL OF ONCOLOGY (2014)
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results
R. Coleman et al.
ANNALS OF ONCOLOGY (2013)
Efficacy of a combined alendronate and calcitriol agent (Maxmarvil®) in Korean postmenopausal women with early breast cancer receiving aromatase inhibitor: a double-blind, randomized, placebo-controlled study
Yumie Rhee et al.
ENDOCRINE JOURNAL (2013)
A Phase 3, Double-blind, Randomised, Parallel-group, Placebo-controlled Study of Oral Weekly Alendronate for the Prevention of Androgen Deprivation Bone Loss in Nonmetastatic Prostate Cancer: The Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) Study
Laurence H. Klotz et al.
EUROPEAN UROLOGY (2013)
Randomized, Double-Blinded, Placebo-Controlled, Trial of Risedronate for the Prevention of Bone Mineral Density Loss in Nonmetastatic Prostate Cancer Patients Receiving Radiation Therapy Plus Androgen Deprivation Therapy
Richard Choo et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2013)
Adjuvant Therapy With Zoledronic Acid in Patients With Breast Cancer: A Systematic Review and Meta-Analysis
Antonis Valachis et al.
ONCOLOGIST (2013)
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases
F. Saad et al.
ANNALS OF ONCOLOGY (2012)
Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results
Shunji Takahashi et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-Month Analysis of the E-ZO-FAST Trial
Antonio Llombart et al.
CLINICAL BREAST CANCER (2012)
Calcium and Vitamin D Supplementation During Androgen Deprivation Therapy for Prostate Cancer: A Critical Review
Mridul Datta et al.
ONCOLOGIST (2012)
Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis
A. Serpa Neto et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2012)
Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis
Eitan Amir et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Breast-Cancer Adjuvant Therapy with Zoledronic Acid
Robert E. Coleman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The Protective Effect of Zoledronic Acid on Bone Loss in Postmenopausal Women with Early Breast Cancer Treated with Sequential Tamoxifen and Letrozole: A Prospective, Randomized, Phase II Trial
Tamar Safra et al.
ONCOLOGY (2011)
Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis
E. Michael Lewiecki
DRUG HEALTHCARE AND PATIENT SAFETY (2011)
Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen
Mitch Dowsett et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prevention of Aromatase Inhibitor-Induced Bone Loss Using Risedronate: The SABRE Trial
Catherine Van Poznak et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Toremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
Matthew R. Smith et al.
JOURNAL OF UROLOGY (2010)
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial
Jack Cuzick et al.
LANCET ONCOLOGY (2010)
RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis
Eva Gonzalez-Suarez et al.
NATURE (2010)
Effects of Exemestane, Anastrozole and Tamoxifen on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Early Breast Cancer Patients: Results of N-SAS BC 04, the TEAM Japan Substudy
T. Aihara et al.
ONCOLOGY (2010)
Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial
Christos Markopoulos et al.
BREAST CANCER RESEARCH (2010)
Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC
Stephanie L. Hines et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Single Infusion of Zoledronic Acid to Prevent Androgen Deprivation Therapy-induced Bone Loss in Men With Hormone-naive Prostate Carcinoma
Takefumi Satoh et al.
CANCER (2009)
Zoledronic Acid Effectively Prevents Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study 36-Month Follow-up Results
Adam M. Brufsky et al.
CLINICAL BREAST CANCER (2009)
Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis
Peyman Hadji
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2009)
Bisphosphonate-associated adverse events
Peter D. Papapetrou
HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM (2009)
Long-term Effectiveness of Adjuvant Goserelin in Premenopausal Women With Early Breast Cancer
Allan Hackshaw et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Intravenous Zoledronic Acid to Prevent Osteoporosis in a Veteran Population With Multiple Risk Factors for Bone Loss on Androgen Deprivation Therapy
Nirmala Bhoopalam et al.
JOURNAL OF UROLOGY (2009)
Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer
Henning Mouridsen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer
Matthew R. Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Risedronate Recovers Bone Loss in Patients With Prostate Cancer Undergoing Androgen-deprivation Therapy
Kouji Izumi et al.
UROLOGY (2009)
Practical guidance for the management of aromatase inhibitor-associated bone loss
P. Hadji et al.
ANNALS OF ONCOLOGY (2008)
Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast Cancer
James E. Lester et al.
CLINICAL CANCER RESEARCH (2008)
Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer
Georgiana K. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230
Richard Eastell et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: Interim analysis of a multicenter phase 3 clinical study
M. R. Smith et al.
JOURNAL OF UROLOGY (2008)
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer:: 5-year follow-up of the ABCSG-12 bone-mineral density substudy
Michael Gnant et al.
LANCET ONCOLOGY (2008)
Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer
M. Dror Michaelson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer - A randomized trial
Susan L. Greenspan et al.
ANNALS OF INTERNAL MEDICINE (2007)
Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study
Robert E. Coleman et al.
LANCET ONCOLOGY (2007)
Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer
Christopher W. Ryan et al.
JOURNAL OF UROLOGY (2006)
Influence of adjuvant anastrozole on bone mineral density in Japanese postmenopausal breast cancer patients: is there a racial difference?
K. Yoneda et al.
ANNALS OF ONCOLOGY (2006)
Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression
J Morote et al.
JOURNAL OF UROLOGY (2006)
Emerging anti-cancer molecular mechanisms of aminobisphosphonates
M Caraglia et al.
ENDOCRINE-RELATED CANCER (2006)
Gonadotropin-releasing hormone agonists and fracture risk: A claims-based cohort study of men with nonmetastatic prostate cancer
MR Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Risk of fracture after androgen deprivation for prostate cancer
VB Shahinian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy
A Sverrisdóttir et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: A randomized controlled trial
MR Smith et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: Effects on bone mineral density and body composition
MR Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer
PR Sieber et al.
JOURNAL OF UROLOGY (2004)
Drug therapy: Aromatase inhibitors in breast cancer
IE Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer
MR Smith et al.
JOURNAL OF UROLOGY (2003)
American society of clinical oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer
BE Hillner et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy
A Berruti et al.
JOURNAL OF UROLOGY (2002)
Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
MR Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials
JGM Klijn et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer
BJ Kiratli et al.
UROLOGY (2001)
Progressive osteoporosis during androgen deprivation therapy for prostate cancer
HW Daniell et al.
JOURNAL OF UROLOGY (2000)
分享论文
